Janux Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Statements of Stockholders’ Equity
For the Three Months Ended March 31, 2024 and 2023
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2023 | 46,252,440 | $46 | $512,401 | $665 | $(168,763) | $344,349 |
| Issuance of common stock and pre-funded common stock warrants, net of $20,896 of issuance costs | 5,397,301 | 5 | 320,071 | — | — | 320,076 |
| Exercise of common stock options | 186,282 | — | 1,657 | — | — | 1,657 |
| Vesting of restricted shares | 4,548 | — | 5 | — | — | 5 |
| Stock-based compensation | — | — | 5,625 | — | — | 5,625 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (1,189) | — | (1,189) |
| Net loss | — | — | — | — | (14,760) | (14,760) |
| Balance at March 31, 2024 | 51,840,571 | $51 | $839,759 | $(524) | $(183,523) | $655,763 |
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2022 | 41,616,260 | $42 | $432,703 | $(1,535) | $(110,470) | $320,740 |
| Exercise of common stock options | 148,649 | — | 1,580 | — | — | 1,580 |
| Vesting of restricted shares | 37,898 | — | 134 | — | — | 134 |
| Stock-based compensation | — | — | 5,473 | — | — | 5,473 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 796 | — | 796 |
| Net loss | — | — | — | — | (17,459) | (17,459) |
| Balance at March 31, 2023 | 41,802,807 | $42 | $439,890 | $(739) | $(127,929) | $311,264 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.